SCHEMBL6350404

SCHEMBL6350404

CN1CCN(c2cncc(OCc3ccccc3)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
HRH3 Q9Y5N1 1/20 0.52
TP53 P04637 1/20 0.52
HTR6 P50406 2/20 0.52
MAP4K1 Q92918 1/20 0.52
HRH4 Q9H3N8 3/20 0.51
MAPT P10636 2/20 0.51
USP2 O75604 1/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 1/20 0.51
ESR2 Q92731 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51
LRRK2 Q5S007 1/20 0.48
CHRNB2 P17787 1/20 0.48
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA7 P36544 1/20 0.48
CHRNA4 P43681 1/20 0.48
PRMT5 O14744 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6359483 0.95 PRMT5 (0.52) NPC1RAB9AHRH3TP53HTR6
SCHEMBL6260293 0.84 PRMT5 (0.58) CHRNB2CHRNA4PRMT5
SCHEMBL23199754 0.83 CHRNB2 (0.54) HRH3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL1134598 0.83 CHRNB2 (0.54) HRH3CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL6415146 0.83 SLC6A7 (0.50) RAB9AMAPTUSP2MAPK1KMT2A
Hydrochloric Acid SCHEMBL6416257 0.83 PRMT5 (0.57) CHRNB2CHRNA4PRMT5
SCHEMBL4178519 0.82 USP2 (0.63) NPC1RAB9AHRH3TP53HTR6
SCHEMBL7678858 0.82 NPC1 (0.67) NPC1RAB9AHRH3TP53MAPT
SCHEMBL3453656 0.81 CHRNB2 (0.57) MAP4K1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL13202898 0.81 RAB9A (0.67) NPC1RAB9AHRH3TP53HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed
CN-1131211-C Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2003-12-17 CN disclosed
CN-1277604-A Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2000-12-20 CN disclosed
EP-1027336-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2000-08-16 EP disclosed
WO-1999021834-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 NPC1 244/4885RAB9A 1957/4885HRH3 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.